Deedwania, Prakash

Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease

Bangalore, S., Fayyad, R., Laskey, R., DeMicco, D. A., Deedwania, P., Kostis, J. B., & Messerli, F. H. (2014) · The American Journal of Medicine

Blood Pressure and Hypertension StudiesCardiovascular Health and Disease Prevention

Cited by 93

Relation of Increased Prebeta-1 High-Density Lipoprotein Levels to Risk of Coronary Heart Disease

Guey, L. T., Pullinger, C. R., Ishida, B. Y., O'Connor, P. M., Zellner, C., Francone, O. L., Laramie, J. M., Naya-Vigne, J. M., Siradze, K. A., Deedwania, P., et al. (2011) · The American Journal of Cardiology

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 70

Renin-angiotensin system inhibition and lower 30-day all-cause readmission in Medicare beneficiaries with heart failure

Sanam, K., Bhatia, V., Bajaj, N. S., Gaba, S., Morgan, C. J., Fonarow, G. C., Butler, J., Deedwania, P., Prabhu, S. D., Wu, W.-C., et al. (2016) · The American Journal of Medicine

Heart Failure Treatment and ManagementRenin-Angiotensin System Studies

Cited by 50

Metabolic and Antihypertensive Effects of Combined Angiotensin Receptor Blocker and Diuretic Therapy in Prediabetic Hypertensive Patients With the Cardiometabolic Syndrome

Zappe, D. H., Sowers, J. R., Hsueh, W. A., Haffner, S. M., Deedwania, P. C., Fonseca, V. A., Keeling, L., & Sica, D. A. (2008) · The Journal of Clinical Hypertension

Blood Pressure and Hypertension StudiesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 42

Sodium glucose co-transporter 2 inhibitors and heart failure.

Ghosh, R. K., Ghosh, G. C., Gupta, M., Bandyopadhyay, D., Akhtar, T., Deedwania, P., Lavie, C. J., Fonarow, G. C., & Aneja, A. (2019) · The American Journal of Cardiology

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 41

Role of High-Dose Beta-Blockers in Patients with Heart Failure with Preserved Ejection Fraction and Elevated Heart Rate

Lam, P. H., Gupta, N., Dooley, D. J., Singh, S., Deedwania, P., Zile, M. R., Bhatt, D. L., Morgan, C. J., Pitt, B., Fonarow, G. C., et al. (2018) · The American Journal of Medicine

Heart Failure Treatment and ManagementHeart rate and cardiovascular health

Cited by 36

Blood Pressure Control in Diabetes Mellitus: Is Lower Always Better, and How Low Should it Go?

Deedwania, P. C. (2011) · Circulation

Blood Pressure and Hypertension StudiesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 29

Updated risk factors should be used to predict development of diabetes

Bethel, M. A., Hyland, K. A., Chacra, A. R., Deedwania, P., Fulcher, G. R., Holman, R. R., Jenssen, T., Levitt, N. S., McMurray, J. J. V., Boutati, E., et al. (2017) · Journal of Diabetes and its Complications

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and Research

Cited by 12

Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial

Kang, Y. M., Giugliano, R. P., Ran, X., Deedwania, P., De Ferrari, G. M., George, J. T., Gouni-Berthold, I., Paiva da Silva Lima, G., Handelsman, Y., Lewis, B. S., et al. (2025) · Diabetes Care

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 9

The Ongoing Saga of Optimal Blood Pressure Level in Patients With Diabetes Mellitus and Coronary Artery Disease

Deedwania, P. (2018) · Journal of the American Heart Association

Blood Pressure and Hypertension StudiesHeart rate and cardiovascular health

Cited by 9